Interpretation of a Screening Trial Before Changing Practice
A hospital committee is asked to adopt annual low-dose CT (LDCT) lung cancer screening for all smokers. They cite a trial in which LDCT reduced lung cancer mortality by 20% (relative) in high-risk smokers aged 55–74 with at least 30 pack-years. However, the same trial reported a 20% relative reduction in all-cause mortality that was not statistically significant, and a high rate of false-positive results requiring follow-up imaging. The committee chair asks you to appraise the evidence and advise on implementation, including who should be screened and how to avoid harms.
1. Appraise the strength and limitations of the evidence and explain how relative versus absolute risk reduction affects your recommendation.
Read the worked answer
The trial provides randomized evidence that LDCT reduces lung cancer–specific mortality in high-risk smokers, which is the outcome that matters for a screening program. However, several caveats apply:
- The all-cause mortality reduction was not statistically significant, meaning the benefit is driven by lung cancer deaths and may be diluted by competing causes in a heavy-smoking population.
- Relative risk reductions overstate benefit: a 20% relative reduction in a disease with, say, a 1% absolute mortality translates to a much smaller absolute benefit (number needed to screen in the hundreds). The committee must communicate absolute numbers.
- Harms: false positives cause anxiety, invasive biopsies, and overdiagnosis of indolent cancers. The trial's strict nodule-management protocol and experienced centers may not generalize.
Recommendation: adopt screening only within a structured program that replicates the trial's eligibility criteria, nodule-tracking protocol (e.g., Lung-RADS), and smoking-cessation support. Do not extrapolate to lighter smokers or those outside the studied age range without evidence.
2. Define the eligible population and the program safeguards you would require before rollout, including how you would audit performance.
Read the worked answer
Eligibility: adults aged 50–80 (or the trial's 55–74 range) with a ≥20–30 pack-year history who currently smoke or quit within the past 15 years, and who are fit for curative treatment if cancer is found. Screening should stop when life expectancy or willingness to undergo treatment is limited.
Safeguards:
- A shared decision-making visit documenting benefits, harms, and the requirement for annual screening.
- Standardized nodule management (Lung-RADS) with a multidisciplinary thoracic team for abnormal findings.
- Smoking-cessation counseling integrated into every screening visit.
- Quality metrics: percentage of eligible patients screened, false-positive rate, biopsy complication rate, stage distribution at diagnosis, and interval cancer rate. Audit annually and compare against trial benchmarks.
Equity: monitor uptake across socioeconomic and language groups to avoid widening disparities. The committee should approve screening as a program with audit, not as a standalone order.